Who Paid My Doc
Research studies in the Open Payments record
139,921 studies have research funding reported against them. Being named on a study as a principal investigator is reported separately from being paid.
Studies
50 of 139,921- M19-117 No ClinicalTrials.gov identifier reported
- M19-128 No ClinicalTrials.gov identifier reported
- M19-130 NCT03978520
- M19-148 NCT04309474
- M19-148 - A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke No ClinicalTrials.gov identifier reported
- M19-161 NCT04274894
- M19-164 NCT04102007
- M19-172 No ClinicalTrials.gov identifier reported
- M19-172 NCT000000NA
- M19-228 NCT03818542
- M19-304 NCT04127695
- M19-306 NCT000000NA
- M19-345 NCT03821935
- M19-345 - Study to Determine the Safety Tolerability Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors No ClinicalTrials.gov identifier reported
- M19-376 No ClinicalTrials.gov identifier reported
- M19-388 NCT03844048
- M19-388 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial No ClinicalTrials.gov identifier reported
- M19-529 NCT000000NA
- M19-530 NCT03969888
- M19-611 NCT04189614
- M19-611 Cofetuzumab Pelidotin Ph1b Recurrent NSCLC NCT04189614
- M19-648 NCT000000NA
- M19-700 NCT04274907
- M19-708 NCT04102020
- M19-708 - A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy No ClinicalTrials.gov identifier reported
- M19-747 NCT04272203
- M19-753 - A Study Evaluating Safety and Tolerability and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm No ClinicalTrials.gov identifier reported
- M19-753 Navitoclax Ph 1 2L MPN NCT04041050
- M19-775 No ClinicalTrials.gov identifier reported
- M19-850 NCT04195698
- M19-893 NCT000000NA
- M19-894 NCT04196283
- M19-939 NCT04223804
- M19-944 NCT04169373
- M19-944 - A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No ClinicalTrials.gov identifier reported
- M19-944 Rinvoq Ph 3 axSpA SELECT-AXIS 2 NCT04169373
- M19-952 NCT000000NA
- M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No ClinicalTrials.gov identifier reported
- M19-968 No ClinicalTrials.gov identifier reported
- M19-973 - Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No ClinicalTrials.gov identifier reported
- M19-974 NCT04254783
- M19-977 NCT04435600
- M19-977 - A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No ClinicalTrials.gov identifier reported
- M19-990 No ClinicalTrials.gov identifier reported
- M19-992 NCT04274933
- M20-009 No ClinicalTrials.gov identifier reported
- m2000 SARS-CoV-2 nasal 510k study No ClinicalTrials.gov identifier reported
- M20-015 No ClinicalTrials.gov identifier reported
- M20-017 NCT000000NA
- M20-040 NCT04430855